Aviragen Therapeutics Inc Stock Nasdaq
Equities
US0537611024
Biotechnology & Medical Research
Sales 2024 * | 14.73M 20.22M | Sales 2025 * | 23.1M 31.71M | Capitalization | 129M 177M |
---|---|---|---|---|---|
Net income 2024 * | -77M -106M | Net income 2025 * | -80M -110M | EV / Sales 2024 * | 8.76 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 5.59 x |
P/E ratio 2024 * |
-1.61
x | P/E ratio 2025 * |
-1.86
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.58% |
Latest transcript on Aviragen Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Sean Tucker
FOU | Founder | - | 03-12-31 |
Phillip Eric Lee
DFI | Director of Finance/CFO | 37 | 22-12-18 |
Michael Finney
CHM | Chairman | 65 | 07-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Yedid
BRD | Director/Board Member | 66 | 19-10-24 |
Elaine Heron
BRD | Director/Board Member | 76 | 22-08-24 |
Michael Finney
CHM | Chairman | 65 | 07-06-30 |
1st Jan change | Capi. | |
---|---|---|
+2.93% | 106B | |
+7.02% | 23.47B | |
-14.60% | 21.9B | |
-7.05% | 18.77B | |
-38.55% | 17.85B | |
-8.83% | 16.78B | |
+5.51% | 14.41B | |
+37.49% | 12.86B | |
+329.39% | 8.78B |